Mumbai, Jan. 30 -- Bajaj Healthcarehas received an approval from the Drug Controller General of India (DCGI) to manufacture both the API and Drug Formulation of Pimavanserin, a 34 mg capsule.

Published by HT Digital Content Services with permission from Capital Market....